This systematic review summarizes the evidence from 2021 to 2025 on the management of dermatological toxicities in the treatment of gynecological cancers with chemotherapy, radiotherapy and targeted therapies. These skin side effects significantly reduce patients' quality of life and their adherence to treatment. The key findings focus on three areas: subclinical skin damage caused by drugs such as paclitaxel, skin problems caused by radiotherapy, and severe effects of new targeted therapies. Innovative technologies, such as 3D printed radiotherapy devices, to prevent and mitigate toxicities were also identified. The review emphasizes the importance of individualized intervention plans and multidisciplinary models of care. The goal is to provide clinicians with information to improve outcomes for patients with skin toxicities, thereby promoting adherence and overall well-being.